NVCR - NASDAQ
NovoCure Limited
$16.15
+2.1%NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
At a Glance
Live SnapshotNovoCure Limited Management Team
Frank Leonard
Chief Executive Officer
Compensation
$974,316
Christoph Brackmann
Chief Financial Officer
Compensation
$1,162,387
Michael Puri
Chief Human Resources Officer
Compensation
$932,882
Uri Weinberg
Chief Innovation Officer & Chief Medical Officer
Compensation
$1,158,934
Mukund Paravasthu
Chief Operating Officer
Compensation
$965,560
William F. Doyle
Executive Chairman
Compensation
$1,777,965
Barak Ben Arye
General Counsel
Compensation
$796,075
Adam Daney
Head of Investor Relations
NovoCure Limited Insider Positioning
During the last 12 months, insiders have sold $1.59M worth of NVCR shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
119.8K
1.59M
-1.6M
-$1.59M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Paravasthu Mukund
Officer: Chief Operating Officer
$667K
Doyle William F
Director, Officer: Executive Chairman
$646K
Weinberg Uri
Officer: Chf Medical And Innovation Ofr
$85K
Brackmann Christoph
Officer: Chief Financial Officer
$85K
Leonard Frank X
Officer: Chief Executive Officer
$75K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.59M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
NVCR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 03, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 21, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 22, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 24, 2023 | April 24, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 25, 2022 | April 25, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | April 27, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 27, 2020 | June 10, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 10, 2019 | May 22, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 20, 2018 | May 31, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 28, 2017 | May 10, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.